Endoscopy Center, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.
Medical Research Center, Shengjing Hospital of China Medical University, Benxi 117000, Liaoning Province, China.
World J Gastroenterol. 2017 Dec 21;23(47):8345-8354. doi: 10.3748/wjg.v23.i47.8345.
To analyze the diagnostic value of a circular RNA (circRNA), circ-LDLRAD3, in pancreatic cancer.
Expression levels of circ-LDLRAD3 were tested in both cells and clinical samples; the latter included 30 paired pancreatic cancer tissues and adjacent non-tumorous tissues, 31 plasma samples from patients with pancreatic cancer, and 31 plasma samples from healthy volunteers. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to measure expression levels of circ-LDLRAD3 in cells and clinical samples; then, the relationship between clinicopathological factors of patient samples and expression of circ-LDLRAD3 in pancreatic cancer was analyzed. The diagnostic value of circ-LDLRAD3 was verified by receiver operating characteristic (ROC) curve analysis.
Circ-LDLRAD3 was up-regulated in pancreatic cancer cell lines ( < 0.01), pancreatic cancer tissues ( < 0.01), and plasma samples from patients with pancreatic cancer ( < 0.01). High expression of circ-LDLRAD3 was significantly associated with venous invasion, lymphatic invasion, and metastasis. The area under the ROC curve of circ-LDLRAD3 alone or combination with CA19-9 was 0.67 and 0.87, respectively, with a sensitivity and specificity of 0.5738 (alone) and 0.7049 (alone), and 0.8033 (combination) and 0.9355 (combination), respectively.
These data suggest that circ-LDLRAD3 may be a biomarker in the diagnosis of pancreatic cancer.
分析环状 RNA（circRNA）circ-LDLRAD3 在胰腺癌中的诊断价值。
检测了细胞和临床样本中 circ-LDLRAD3 的表达水平；后者包括 30 对胰腺癌组织和相邻非肿瘤组织、31 例胰腺癌患者血浆样本和 31 例健康志愿者血浆样本。实时定量逆转录聚合酶链反应（qRT-PCR）用于测量细胞和临床样本中 circ-LDLRAD3 的表达水平；然后分析患者样本的临床病理因素与胰腺癌中 circ-LDLRAD3 表达的关系。通过接收者操作特征（ROC）曲线分析验证了 circ-LDLRAD3 的诊断价值。
circ-LDLRAD3 在胰腺癌细胞系中上调（<0.01）、胰腺癌组织中上调（<0.01）和胰腺癌患者血浆样本中上调（<0.01）。circ-LDLRAD3 的高表达与静脉侵犯、淋巴侵犯和转移显著相关。circ-LDLRAD3 单独或与 CA19-9 联合的 ROC 曲线下面积分别为 0.67 和 0.87，单独的灵敏度和特异性分别为 0.5738（单独）和 0.7049（单独），联合的灵敏度和特异性分别为 0.8033（联合）和 0.9355（联合）。
这些数据表明 circ-LDLRAD3 可能是胰腺癌诊断的生物标志物。
